Modality
Radioligand
MOA
CAR-T CD19
Target
SMN2
Pathway
Autophagy
EoEFSGSRB
Development Pipeline
Preclinical
~Nov 2017
→ ~Feb 2019
Phase 1
May 2019
→ Jul 2030
Phase 1Current
NCT03425202
2,509 pts·EoE
2019-05→2028-11·Completed
NCT04209800
438 pts·RB
2020-10→2030-07·Active
2,947 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-11-192.6y awayInterim· EoE
2030-07-104.3y awayInterim· RB
Trial Timeline
Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P1
Complet…
P1
Active
Catalysts
Interim
2028-11-19 · 2.6y away
EoE
Interim
2030-07-10 · 4.3y away
RB
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03425202 | Phase 1 | EoE | Completed | 2509 | PASI75 |
| NCT04209800 | Phase 1 | RB | Active | 438 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| REG-647 | Regeneron | Preclinical | SMN2 | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Talasotorasib | Exelixis | Preclinical | APOC3 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| Elracapivasertib | Kymera | Phase 3 | PRMT5 |